CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
Go back to CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder| CalAmp Corp. (NASDAQ: CAMP) | Delayed: 4.19 -0.03 (0.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.22 | 52 Week High | $21.34 | |||
| Open | $4.22 | 52 Week Low | $12.13 | |||
| Day High | $4.46 | P/E | 3.15 | |||
| Day Low | $4.16 | EPS | $1.33 | |||
| Volume | 41,032 | |||||
